Alto Neuroscience, Inc.
As of Oct 22, 2026, Alto Neuroscience is in Stage 3, the topping phase, now in week 2 (since Oct 13, 2026). It closed at $22.20, 39.4% below its 52-week high and below its 200-day average, which is rising.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ANRO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ANRO among Biotechnology43rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …43 | ANRO | Stage 3 · wk 2 | 95 | −19.3% |
Alto Neuroscience: quick answers
What stage is Alto Neuroscience in?
As of Oct 22, 2026, Alto Neuroscience (ANRO) is in Stage 3, the topping phase. It entered Stage 3 on Oct 13, 2026 and is in week 2. What the four stages mean
Is Alto Neuroscience in an uptrend?
Its uptrend has stalled. Alto Neuroscience is in Stage 3, the topping phase that follows an advance. It trades 7.8% below its 200-day average, which is rising.
How far is Alto Neuroscience from its 52-week high?
Alto Neuroscience closed at $22.20 on Oct 22, 2026, 39.4% below its 52-week high of $36.64. Its 52-week low is $10.20.
How has Alto Neuroscience performed over the past year?
As of Oct 22, 2026, Alto Neuroscience is up 104.6% over the past year and up 33.8% so far in 2026.
Which sector and industry is Alto Neuroscience in?
Alto Neuroscience is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.